Prevalence of chronic hepatitis B and C in psoriasis patients: A cross-sectional study in a large US population To the Editor: An association between psoriasis and hepatitis B and C is inconsistently reported in the literature. [1] [2] [3] Because both hepatitis B and C viruses have been hypothesized to exacerbate psoriasis and because biologic treatments for psoriasis may be contraindicated in patients infected with hepatitis viruses, exploring this possible relationship for each virus may lead to better management. 1 Consequently, this study aimed to determine the prevalence of hepatitis B and C in patients with psoriasis within a large, single-center, US patient population.
Under an Institutional Review Boardeapproved protocol, we utilized a large, urban, electronic medical record data repository, Northwestern Medicine Enterprise Data Warehouse (NMEDW) with data on more than 4 million individuals. 4 A very high percentage of the patients in the NMEDW data repository are from the Chicago metropolitan area. A very small minority of patients are from surrounding states and/or rural areas. All patients, regardless of billing status, are included. We searched the NMEDW for all patients aged 18 to 89 years who underwent hepatitis B and/or C serology screening between September 2010 and September 2016. We then divided this group into those with a diagnosis of psoriasis . Logistic regression analysis was performed to obtain odds ratios (ORs) with 95% confidence intervals (CIs) and corresponding P values.
A total of 114,855 patients underwent hepatitis B and/or C screening (Table I ). The frequency of hepatitis B and/or C is shown in Table II . There was no significant difference between the populations with and without psoriasis in terms of prevalence of hepatitis B (OR, 0.56; 95% CI, 0.34-1.03; P ¼ .064) or hepatitis C (OR, 0.8; 95% CI, 0.57-1.13; P ¼ .2).
Using a cross-sectional design to analyze a large, urban, single-center, midwestern US patient population, this study found no significant difference in prevalence for chronic hepatitis B or C in patients with psoriasis compared with in those without psoriasis. Limitations of this study include the cross-sectional design, the lack of adjustment for additional risk factors for hepatitis B and C, and the inability to assess prevalence of hepatitis B and/or C in patients with psoriasis who were not screened for hepatitis. Additionally, prevalence might have been affected by differences in demographics between psoriasis and control populations. Moreover, this study, although informed by data on a large number of patients, was conducted in a single, urban, multiethnic, academic-based medical center and is therefore not viewed as representative of the general population. Strengths of this study include its large cohort size, representation across sexes, and serology-based diagnostic capability for chronic hepatitis (B and C). Our findings of no statistically significant association between psoriasis and chronic hepatitis B and/or C in this large US population contribute to the limited existing literature to allow for a greater clarity of risk assessment, especially for that of viral reactivation.
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Smoking and risk of psoriasis: A nationwide cohort study
To the Editor: Smoking is a health hazard and also a potential risk factor for psoriasis.
1,2 Several studies previously showed an association between smoking and the severity of psoriasis. 2, 3 However, because of their small size, the results were inconclusive. We therefore examined the independent relationship between smoking status and psoriasis by performing a large-scale nationwide cohort study (institutional review board No. KC17EISE0012). We used the representative database of the Korean National Health Insurance from 2005 through 2015. A total of 17,055,608 subjects over the age of 20 years who underwent a health examination in 2005-2008 were followed for 8 years. The incidence ratio (IR) of psoriasis with a 95% confidence interval (CI) adjusted for age, sex, alcohol consumption, physical activity, body mass index, and comorbidities was estimated by Poisson regression. The hazard ratio (HR) was estimated by Cox regression analysis.
The reference group comprised individuals who had never smoked (Table I ). The IR ( per 1000) of psoriasis was 3.71 for former smokers and 3.54 for current smokers, respectively. In multivariate analyses, compared with nonsmokers, former smokers (adjusted IR, 1.11; 95% CI, 1.10-1.12) and current smokers (adjusted IR, 1.14; 95% CI, 1.13-1.15) had a significantly higher risk for development of psoriasis. These results indicate that smoking status is an independent potential risk factor for psoriasis. In addition, the risk for psoriasis was increased with amount and duration of smoking (P for trend \.0001) (Fig 1) . There was a statistically significant positive correlation between risk for psoriasis and total period of smoking (P for trend \.0001). Furthermore, the HR for psoriasis was lowest in individuals who had smoked fewer than 0.5 packs 
